The Cancer News
AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Research
The volume and pace of cancer research, from preclinical studies to clinical trials and FDA approvals, can make it challenging to stay informed. This section highlights the latest developments and translates complex scientific concepts into clear, accessible insights for both healthcare professionals and the broader public.
Precision Frontiers in Hepatobiliary Oncology: Evaluating FGFR2 Selectivity and the Evolving Role of Immunotherapy
By Gentry George Teng King, MD
Expert analysis of FGFR2-targeted therapy in intrahepatic cholangiocarcinoma and the evolving role of immunotherapy in hepatocellular carcinoma, from adjuvant setbacks to perioperative and first-line advances.
Precision Frontiers in Hepatobiliary Oncology: Evaluating FGFR2 Selectivity and the Evolving Role of Immunotherapy
By Gentry George Teng King, MD
Expert analysis of FGFR2-targeted therapy in intrahepatic cholangiocarcinoma and the evolving role of immunotherapy in hepatocellular carcinoma, from adjuvant setbacks to perioperative and first-line advances.
Precision Frontiers in Hepatobiliary Oncology: Evaluating FGFR2 Selectivity and the Evolving Role of Immunotherapy
By Gentry George Teng King, MD
Expert analysis of FGFR2-targeted therapy in intrahepatic cholangiocarcinoma and the evolving role of immunotherapy in hepatocellular carcinoma, from adjuvant setbacks to perioperative and first-line advances.
Nepal’s Cancer Burden: A Systematic Review and Meta-Analysis of 15 Years of Evidence
By Dr. Roshan Kumar Mahato
A comprehensive systematic review reveals Nepal’s rising cancer burden, highlighting late-stage diagnoses, financial toxicity, and the urgent need for national data to guide cancer control strategies.
Nepal’s Cancer Burden: A Systematic Review and Meta-Analysis of 15 Years of Evidence
By Dr. Roshan Kumar Mahato
A comprehensive systematic review reveals Nepal’s rising cancer burden, highlighting late-stage diagnoses, financial toxicity, and the urgent need for national data to guide cancer control strategies.
Nepal’s Cancer Burden: A Systematic Review and Meta-Analysis of 15 Years of Evidence
By Dr. Roshan Kumar Mahato
A comprehensive systematic review reveals Nepal’s rising cancer burden, highlighting late-stage diagnoses, financial toxicity, and the urgent need for national data to guide cancer control strategies.
Top Clinical Takeaways from SABCS 2025: What Oncologists Need to Know Now
By Zunairah Shah, MD
Key practice-changing insights from SABCS 2025, including earlier use of antibody–drug conjugates, the rise of oral SERDs, mutation-guided endocrine therapy, and evolving treatment sequencing across breast cancer subtypes.
Top Clinical Takeaways from SABCS 2025: What Oncologists Need to Know Now
By Zunairah Shah, MD
Key practice-changing insights from SABCS 2025, including earlier use of antibody–drug conjugates, the rise of oral SERDs, mutation-guided endocrine therapy, and evolving treatment sequencing across breast cancer subtypes.
Top Clinical Takeaways from SABCS 2025: What Oncologists Need to Know Now
By Zunairah Shah, MD
Key practice-changing insights from SABCS 2025, including earlier use of antibody–drug conjugates, the rise of oral SERDs, mutation-guided endocrine therapy, and evolving treatment sequencing across breast cancer subtypes.
Dr. Gentry King on Advances in Hepatocellular Carcinoma and Biliary Tract Cancers: From Targeted Therapy to Advanced Treatment Strategies
By The Cancer News Team
Dr. Gentry King reviews the latest advances in hepatocellular carcinoma and biliary tract cancers, highlighting FGFR2-targeted therapy, immune checkpoint inhibitors, and evolving strategies across BCLC stages.
Dr. Gentry King on Advances in Hepatocellular Carcinoma and Biliary Tract Cancers: From Targeted Therapy to Advanced Treatment Strategies
By The Cancer News Team
Dr. Gentry King reviews the latest advances in hepatocellular carcinoma and biliary tract cancers, highlighting FGFR2-targeted therapy, immune checkpoint inhibitors, and evolving strategies across BCLC stages.
Dr. Gentry King on Advances in Hepatocellular Carcinoma and Biliary Tract Cancers: From Targeted Therapy to Advanced Treatment Strategies
By The Cancer News Team
Dr. Gentry King reviews the latest advances in hepatocellular carcinoma and biliary tract cancers, highlighting FGFR2-targeted therapy, immune checkpoint inhibitors, and evolving strategies across BCLC stages.
Dr. Rachael A. Safyan on Pancreatic Cancer: Evolving Treatment Paradigms from Resectable to Metastatic Disease
By The Cancer News Team
Dr. Rachael A. Safyan reviews evolving treatment strategies in pancreatic cancer, from neoadjuvant therapy and tumor-treating fields to RAS-targeted agents reshaping metastatic care.
Dr. Rachael A. Safyan on Pancreatic Cancer: Evolving Treatment Paradigms from Resectable to Metastatic Disease
By The Cancer News Team
Dr. Rachael A. Safyan reviews evolving treatment strategies in pancreatic cancer, from neoadjuvant therapy and tumor-treating fields to RAS-targeted agents reshaping metastatic care.
Dr. Rachael A. Safyan on Pancreatic Cancer: Evolving Treatment Paradigms from Resectable to Metastatic Disease
By The Cancer News Team
Dr. Rachael A. Safyan reviews evolving treatment strategies in pancreatic cancer, from neoadjuvant therapy and tumor-treating fields to RAS-targeted agents reshaping metastatic care.
Dr. David Zhen Discusses Advances in Neuroendocrine Tumor Treatment: From Emerging Systemic Therapies to Next-Generation Radioligand Strategies
By The Cancer News Team
Dr. David Zhen reviews major advances in neuroendocrine tumor treatment, including cabozantinib approval, earlier use of PRRT, emerging alpha-emitter radioligand therapies, and novel targeted agents.
Dr. David Zhen Discusses Advances in Neuroendocrine Tumor Treatment: From Emerging Systemic Therapies to Next-Generation Radioligand Strategies
By The Cancer News Team
Dr. David Zhen reviews major advances in neuroendocrine tumor treatment, including cabozantinib approval, earlier use of PRRT, emerging alpha-emitter radioligand therapies, and novel targeted agents.
Dr. David Zhen Discusses Advances in Neuroendocrine Tumor Treatment: From Emerging Systemic Therapies to Next-Generation Radioligand Strategies
By The Cancer News Team
Dr. David Zhen reviews major advances in neuroendocrine tumor treatment, including cabozantinib approval, earlier use of PRRT, emerging alpha-emitter radioligand therapies, and novel targeted agents.
Dr. Emerson Y. Chen on Perioperative Chemoimmunotherapy and HER2-Directed Therapies in Resectable and Advanced Gastric Cancer
By The Cancer News Team
Dr. Emerson Y. Chen reviews MATTERHORN, HERIZON-GEA-01, and DESTINY-Gastric04, highlighting perioperative nivolumab plus FLOT and next-generation HER2-directed therapies in advanced gastroesophageal cancer.
Dr. Emerson Y. Chen on Perioperative Chemoimmunotherapy and HER2-Directed Therapies in Resectable and Advanced Gastric Cancer
By The Cancer News Team
Dr. Emerson Y. Chen reviews MATTERHORN, HERIZON-GEA-01, and DESTINY-Gastric04, highlighting perioperative nivolumab plus FLOT and next-generation HER2-directed therapies in advanced gastroesophageal cancer.
Dr. Emerson Y. Chen on Perioperative Chemoimmunotherapy and HER2-Directed Therapies in Resectable and Advanced Gastric Cancer
By The Cancer News Team
Dr. Emerson Y. Chen reviews MATTERHORN, HERIZON-GEA-01, and DESTINY-Gastric04, highlighting perioperative nivolumab plus FLOT and next-generation HER2-directed therapies in advanced gastroesophageal cancer.
Why Indigenous Communities Face Higher Cancer Rates
By Jin Mou, MD, MSc, MPH, PhD
New data show Indigenous communities face higher rates of gallbladder and biliary cancers, with emerging research suggesting distinct genetic and biological drivers in Alaska Native and Pacific Islander populations.
Why Indigenous Communities Face Higher Cancer Rates
By Jin Mou, MD, MSc, MPH, PhD
New data show Indigenous communities face higher rates of gallbladder and biliary cancers, with emerging research suggesting distinct genetic and biological drivers in Alaska Native and Pacific Islander populations.
Why Indigenous Communities Face Higher Cancer Rates
By Jin Mou, MD, MSc, MPH, PhD
New data show Indigenous communities face higher rates of gallbladder and biliary cancers, with emerging research suggesting distinct genetic and biological drivers in Alaska Native and Pacific Islander populations.
Can a Blood Test Detect Cancer Earlier? What to Know About Liquid Biopsy
By The Cancer News Team
A new study suggests multicancer blood tests could shift cancer diagnoses to earlier stages. Here’s what liquid biopsy is, how MCED tests work, current FDA approvals, benefits, risks, and what patients should know.
Can a Blood Test Detect Cancer Earlier? What to Know About Liquid Biopsy
By The Cancer News Team
A new study suggests multicancer blood tests could shift cancer diagnoses to earlier stages. Here’s what liquid biopsy is, how MCED tests work, current FDA approvals, benefits, risks, and what patients should know.
Can a Blood Test Detect Cancer Earlier? What to Know About Liquid Biopsy
By The Cancer News Team
A new study suggests multicancer blood tests could shift cancer diagnoses to earlier stages. Here’s what liquid biopsy is, how MCED tests work, current FDA approvals, benefits, risks, and what patients should know.
Dr. Julia Zhang on Challenging Treatment Dogma: Early Bispecific Antibody Use in Relapsed Myeloma
By The Cancer News Team
An expert panel at Best of Hematology & Breast Cancer 2026 debates early use of bispecific antibodies versus CAR T-cell therapy in an 83-year-old patient with relapsed multiple myeloma.
Dr. Julia Zhang on Challenging Treatment Dogma: Early Bispecific Antibody Use in Relapsed Myeloma
By The Cancer News Team
An expert panel at Best of Hematology & Breast Cancer 2026 debates early use of bispecific antibodies versus CAR T-cell therapy in an 83-year-old patient with relapsed multiple myeloma.
Dr. Julia Zhang on Challenging Treatment Dogma: Early Bispecific Antibody Use in Relapsed Myeloma
By The Cancer News Team
An expert panel at Best of Hematology & Breast Cancer 2026 debates early use of bispecific antibodies versus CAR T-cell therapy in an 83-year-old patient with relapsed multiple myeloma.